Preventing and Managing Toxicities of High-Dose Methotrexate - Wikidata - wikimedia - TriplyDB

Preventing and Managing Toxicities of High-Dose Methotrexate

Preventing and Managing Toxicities of High-Dose Methotrexate

http://www.wikidata.org/entity/Q37496637

about

Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.Selective Cell Penetrating Peptide-Functionalized Polymersomes Mediate Efficient and Targeted Delivery of Methotrexate Disodium to Human Lung Cancer In Vivo.High incidence of acute kidney injury during chemotherapy for childhood acute myeloid leukemia.Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?Treatment of severe drug reactions by hemodialysis.Is it really safe to withhold folinic acid when less than 1000 mg/m2 methotrexate is ingested?Hispanic ethnicity as a risk factor for requiring glucarpidase rescue in pediatric patients receiving high-dose methotrexate.Vanillin mitigates the adverse impact of cisplatin and methotrexate on rat kidneys.Evaluation, Identification, and Management of Acute Methotrexate Toxicity in High-dose Methotrexate Administration in Hematologic Malignancies.Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function.A Rapidly Fatal Case of Low-Dose Methotrexate Toxicity.Osteogenic Sarcoma in an Adolescent With Cystic Fibrosis: Successful Treatment Despite Significant Obstacles The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients Histidine catabolism is a major determinant of methotrexate sensitivity Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate

P2860

Q38844526-6CDEC18E-4985-45BF-9BF6-259E1EE01567 Q47216864-F20A8376-FE08-411C-96A9-732801F339E6 Q47234674-D43A3A01-B1B5-4D3F-8D06-80A5FBE48FCB Q47250639-AB7FB9CE-FF0F-4952-BC9A-9D9D86A4D7AB Q47600128-2609D1C3-AA65-4AE2-88AE-EFFA37843DC1 Q48232372-EF1A81EB-F6EA-4FF2-8A1F-DADBA4B8AE37 Q48336764-F5CCA7A9-006E-4257-8DDA-A83D5213EC17 Q50026202-9A00E89A-BF7F-4E85-AF19-6C6E8544FA26 Q52355076-E7C9BDF2-2B16-45D3-986A-D13AF4B3162B Q55021000-D429B078-1AEC-415F-8064-4029C3DFC031 Q55616454-BB7D4E97-F12D-4AA3-9D2F-523CE9AD5486 Q57300050-77B51B14-8501-4E8F-9E88-1D0C74ABD4EC Q57816122-1C1CE437-5000-4FFA-9A5A-1A35B766D805 Q59071518-F3C64F19-F375-44ED-9C0C-B7958C20FC0B Q59135667-92CD0C8D-1B18-4F08-AC1F-603416A7AD48

P2860

Preventing and Managing Toxicities of High-Dose Methotrexate

http://www.wikidata.org/entity/Q37496637

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Preventing and Managing Toxicities of High-Dose Methotrexate

@en

Preventing and Managing Toxicities of High-Dose Methotrexate.

@nl

type

label

Preventing and Managing Toxicities of High-Dose Methotrexate

@en

Preventing and Managing Toxicities of High-Dose Methotrexate.

@nl

prefLabel

Preventing and Managing Toxicities of High-Dose Methotrexate

@en

Preventing and Managing Toxicities of High-Dose Methotrexate.

@nl

P1433

Q37496637-66812BCE-D7E8-44F1-B9AC-9861F7E4029E

P1476

Q37496637-29B90B4F-8B50-4044-B353-00DEA2B20321

P2093

Q37496637-59167249-50B1-40BE-90C2-9891CB5FD66D

Q37496637-E367F5F0-39A0-4D38-9179-9C3FDF25A843

Q37496637-E590FEBD-FD75-42B7-B5F4-88C9A1B6D0DB

Q37496637-FD0C8F13-FB5C-4EC0-A178-CC057B78CAE7

P2860

Q37496637-02C36CAF-AD0C-461C-9478-201F5B3A357E

Q37496637-052753EA-672D-4A35-80B7-3D2310BF57AF

Q37496637-06937A82-E2E1-4D9C-B847-FE1F4842A8A8

Q37496637-071BAC39-7F6C-4272-942C-453C27446D23

Q37496637-090B7560-1DF2-4685-92E3-6713757B6C2B

Q37496637-0C029016-0048-4638-B4C8-8949CD4E8CE3

Q37496637-0D4C8313-AADB-4F15-9D11-13005605F8EE

Q37496637-11984408-6395-462B-828F-870786AB7F16

Q37496637-132426DB-63A4-4273-A034-D86073D2C8B7

Q37496637-155BA27B-358F-48A8-B5E6-E28CCB39B332

P304

Q37496637-0F6476F9-7503-448A-8667-ADEAAA462674

P31

Q37496637-4A0FB23F-CEA5-424A-8176-0CFB23A328D5

Q37496637-AE7DFEA4-8D6B-4FEF-BBEA-38E7CFB48AF1

P356

Q37496637-2F0463C8-B60B-463D-B0A6-BCEAC37D8C73

P433

Q37496637-63732524-D2F7-4516-BEB1-46AA56C5E6A4

P478

Q37496637-4DBA4E46-98BE-4FCA-88A8-138A5E029DE5

P50

Q37496637-2AEB33CF-34BE-404E-A3E6-71748165425B

P577

Q37496637-73F67286-187D-435C-9FA4-00ECE0897AAB

Q37496637-B201C455-7C37-49D9-B030-B62C66EFCF48

P698

Q37496637-92A64B60-6BE9-4A64-831D-993AF8FC63A3

P921

Q37496637-B1CBFAEE-1CF7-44B0-A293-ADB0A468E28B

P932

Q37496637-E1630051-293B-4A6E-B1D1-0CEAE9240A2D

P356

THEONCOLOGIST.2015-0164

P1433

P1476

Preventing and Managing Toxicities of High-Dose Methotrexate

@en

P2093

John McCormick

http://www.w3.org/2001/XMLSchema#string

R Donald Harvey

http://www.w3.org/2001/XMLSchema#string

Randall K Buddington

http://www.w3.org/2001/XMLSchema#string

Scott C Howard

http://www.w3.org/2001/XMLSchema#string

P2860

Interventions for preventing oral mucositis for patients with cancer receiving treatment

Interventions for treating oral mucositis for patients with cancer receiving treatment

Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics

Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.

Effectiveness of high-dose infusions of methotrexate followed by leucovorin in carcinoma of the head and neck.

Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.

The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.

High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis.

Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

P304

1471-1482

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2015-0164

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27496039

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

P932

5153332

http://www.w3.org/2001/XMLSchema#string